The separate federal case centers on claims that he used laboratory businesses to bill Medicare for unnecessary, unordered, or unperformed respiratory tests during the COVID-19 pandemic.
WASHINGTON, DC — Patrick Britton-Harr is scheduled to return to federal court in Baltimore on October 13, 2026, for a separate healthcare fraud trial that will examine allegations involving more than $15 million in Medicare claims submitted through his laboratory company during the COVID-19 emergency.
The approaching proceeding is distinct from the AeroVanti private-aviation prosecution that produced six wire fraud convictions in June, although the two cases have become closely connected in the public record because prosecutors portray both as chapters in a broader pattern of business deception.
According to a July federal court status report and several contemporaneous accounts, October 13 remains the operative trial date, correcting an August news report that cited October 3, even though that date falls on a Saturday and conflicts with the docketed schedule.
The Justice Department’s charging announcement says Britton-Harr faces five counts of healthcare fraud and one count of transactional money laundering, with each count carrying a potential maximum prison term of ten years if prosecutors obtain convictions.
Britton-Harr has pleaded not guilty, and every allegation in the indictment remains unproven unless federal prosecutors establish guilt beyond a reasonable doubt before a unanimous jury, a distinction that remains essential despite his conviction in the legally separate aviation case.
A Pandemic Testing Offer Becomes a Medicare Case
Prosecutors allege Britton-Harr, working through Provista Health, offered COVID-19 screening services to nursing homes across the country when administrators, residents, families, and medical professionals were confronting severe uncertainty about outbreaks inside facilities housing especially vulnerable older adults.
The government contends that the screening arrangement created access to beneficiary information and patient specimens that could be used to submit claims not only for coronavirus testing, but also for expensive respiratory pathogen panel testing carrying significantly higher Medicare reimbursement.
Respiratory pathogen panels can identify multiple viral or bacterial targets from a single specimen, but Medicare coverage ordinarily depends upon medical necessity, proper physician authorization, accurate documentation, and evidence that the billed analysis was actually performed for the beneficiary identified on the claim.
The indictment alleges those requirements were repeatedly absent because patients often lacked symptoms supporting the additional panels, treating physicians had not ordered the tests, and numerous billed analyses were never completed despite claims representing that covered laboratory services had occurred.
Federal prosecutors say Provista caused more than $15 million in allegedly fraudulent respiratory-panel claims to reach Medicare, while the government program ultimately paid more than $5 million before investigators and administrators unraveled the billing activity underlying the criminal accusations.
Those figures reflect alleged claims and payments rather than a final criminal loss determination, so trial evidence, judicial rulings, jury findings, and any later sentencing calculations will determine what conduct and financial amounts can legally be attributed to Britton-Harr.
Why Nursing-Home Testing Matters
Nursing homes became particularly sensitive enforcement territory during the pandemic because residents faced elevated health risks, facilities depended upon rapid diagnostic services, and emergency conditions created unusual opportunities for laboratories or marketers to attach lucrative additional billing to broadly offered screening programs.
Prosecutors are expected to argue that a legitimate offer of COVID-19 screening became the front door for unrelated respiratory panels, allowing the alleged scheme to appear medically responsive while generating reimbursements that depended upon representations concerning necessity, orders, performance, and patient status.
The government’s theory therefore reaches beyond a disagreement about aggressive billing, because the indictment describes claims allegedly submitted without treating-physician authorization and tests allegedly billed despite never being performed, factual propositions that would directly challenge the truthfulness of Medicare submissions.
Britton-Harr’s defense may contest the government’s interpretation of laboratory workflows, ordering practices, corporate responsibility, billing knowledge, or intent, because criminal healthcare fraud requires more than demonstrating administrative mistakes, deficient paperwork, disputed coverage, or an ordinary business failure.
To convict, prosecutors must prove the charged scheme and Britton-Harr’s knowing, willful participation under the applicable federal statute, while the defense can challenge whether employees, contractors, laboratories, software systems, or third-party billing personnel created errors without criminal direction from him.
Claims Involving Deceased Beneficiaries
One of the government’s most striking contentions emerged first in a related civil False Claims Act case, where officials alleged that more than 300 claims identified specimen-collection dates occurring after the Medicare beneficiaries listed on those submissions had already died.
That allegation will attract attention because post-death collection dates appear readily understandable to jurors, yet prosecutors must still authenticate the relevant records, connect them to charged criminal conduct, demonstrate how the claims were produced, and establish Britton-Harr’s legally required state of mind.
The defense, meanwhile, can examine whether dates resulted from coding conventions, delayed data entry, mismatched patient files, external billing processes, corrected claims, or other operational explanations, although any explanation would need to withstand comparison against death records and laboratory documentation.
Evidence concerning deceased beneficiaries could become especially influential if the government shows repeated, similarly structured transactions rather than isolated anomalies, since recurring patterns may help prosecutors argue that the submissions reflected a deliberate system rather than accidental clerical failures.
Jurors will nevertheless receive instructions requiring them to assess each criminal count independently, preventing the emotional force of the most unusual allegation from replacing the government’s obligation to prove every statutory element associated with each charged transaction.
The Money-Laundering Count
Alongside five healthcare fraud counts, the indictment charges transactional money laundering under a federal statute addressing certain monetary transactions involving criminally derived property valued above the statutory threshold, thereby placing the movement and use of alleged proceeds directly before the jury.
That charge requires the government to establish more than the existence of Medicare payments, because prosecutors must connect the identified transaction to proceeds of specified unlawful activity and prove the knowledge and value elements required by the money-laundering statute.
Financial records, bank transfers, corporate ledgers, ownership documents, emails, and testimony from accountants or investigators may therefore occupy substantial trial time, translating the government’s narrative from disputed laboratory claims into a traceable account of where Medicare reimbursements allegedly traveled.
The defense can respond by arguing that transferred funds represented commingled business revenue, legitimate operating income, money controlled by another participant, or proceeds Britton-Harr did not know were associated with unlawful activity when the charged transaction occurred.
This financial component also explains why the prosecution may reach across multiple related entities, since ownership and control evidence can help jurors evaluate whether separate companies performed genuine operational roles or functioned primarily as channels for disputed Medicare revenue.
Civil Judgment Came Before the Criminal Indictment
The criminal trial follows a civil enforcement action filed in July 2023 against Britton-Harr and several companies, including Provista Health, AMS Onsite, Britton-Harr Enterprises, Coastal Laboratories, and Coastal Management Group, over substantially related laboratory-billing allegations.
In July 2024, the federal court entered default judgments totaling approximately $26.34 million after Britton-Harr and the corporate defendants failed to defend the government’s claims, producing a major civil outcome without a trial resolving the evidence on its merits.
A default judgment is not a criminal conviction, and it does not relieve prosecutors of proving the new indictment beyond a reasonable doubt, although the surrounding civil proceedings could create evidentiary disputes concerning prior statements, financial restrictions, corporate records, and litigation conduct.
The different burdens are crucial because civil False Claims Act liability is decided under standards distinct from criminal guilt, while criminal jurors must focus on admissible evidence tied to the six charged counts rather than treating the earlier judgment as automatic proof.
The government announced the criminal indictment in May 2025, nearly two years after commencing its civil lawsuit, showing how federal authorities can pursue parallel or sequential remedies when the alleged conduct may support both recovery of public funds and individual punishment.
A Separate Case From the AeroVanti Conviction
Britton-Harr entered the approaching healthcare trial with a transformed legal position after a Baltimore jury convicted him in June 2026 of six wire fraud counts arising from AeroVanti, the private flight club he founded and controlled.
Evidence in that aviation trial showed customers paid approximately $15 million through upfront Top Gun memberships after receiving promises that their funds would help purchase five specific aircraft and that aircraft titles would protect their financial interests through escrow arrangements.
The jury accepted prosecutors’ contention that the promised aircraft were not purchased with those member funds and that substantial amounts instead supported yachts, jewelry, personal living expenses, and a costly rental property near Tampa, Florida.
Britton-Harr has requested a new trial in the AeroVanti matter based upon alleged interactions between jurors and a former courtroom deputy, and a judicial hearing on that motion was scheduled after his original August sentencing date was postponed.
As recent news coverage of the scheduling dispute confirms, the Medicare trial was assigned October 13 well before the aviation verdict, and later litigation over courtroom conduct has not publicly displaced that separate healthcare date.
What the Jury May Hear
The government’s witness list could include federal agents, Medicare claims specialists, nursing-home personnel, treating physicians, laboratory workers, billing professionals, corporate employees, and financial investigators who can connect patient-level records with submissions, reimbursements, and subsequent transfers.
Physicians may be particularly important if they deny ordering tests attributed to them, because their testimony could give jurors direct evidence about whether claimed authorizations existed and whether any beneficiary symptoms supported broad respiratory-panel analysis.
Laboratory witnesses could explain specimen custody, accession numbers, machine runs, result reporting, and billing files, enabling jurors to determine whether particular tests were performed and whether Provista’s claims accurately described completed clinical work.
Medicare experts will likely explain coverage requirements and claims data in accessible terms, while the defense can test whether program rules were clear during an unprecedented emergency that brought rapid waivers, shifting guidance, operational confusion, and enormous testing demand.
Digital records may also become central because emails, spreadsheets, text messages, billing exports, and bank metadata can show who made decisions, what warnings circulated internally, and whether disputed practices continued after employees or outside professionals raised concerns.
The trial’s outcome may ultimately turn upon attribution, since ownership of a healthcare company does not by itself prove personal criminal intent, but documented directions, approvals, concealment efforts, or financial control could permit jurors to infer knowledge from circumstantial evidence.
Potential Defense Themes
Britton-Harr’s lawyers may emphasize that pandemic-era laboratory operations expanded under extraordinary pressure, making imperfect documentation or mismatched claims more plausible without establishing a deliberate plan to steal from Medicare or launder government reimbursements.
They may also challenge the reliability of cooperating witnesses, particularly if former employees or business partners received favorable treatment, immunity, reduced exposure, or other incentives that could influence their recollections and descriptions of corporate decision-making.
Another likely dispute concerns whether broad or standing physician orders satisfied applicable requirements, because prosecutors characterize many panels as unordered while the defense may argue facilities, medical directors, or authorized practitioners created valid testing protocols during the emergency.
Expert testimony could become decisive on medical necessity, since the government may portray panels for asymptomatic residents as unjustified while defense specialists might explain why congregate-care outbreaks, overlapping symptoms, or differential diagnosis sometimes supported broader pathogen testing.
The court will determine which evidence from the civil case and AeroVanti prosecution may reach the healthcare jury, balancing probative value against unfair prejudice and guarding against a verdict based merely upon Britton-Harr’s unrelated conviction or public reputation.
The Stakes Beyond One Defendant
The Britton-Harr prosecution reflects a wider federal effort to examine pandemic programs, emergency reimbursements, laboratory arrangements, and nursing-home testing models that moved vast public resources quickly while conventional compliance systems struggled to keep pace.
Healthcare fraud cases involving unnecessary testing matter beyond direct monetary loss because excessive diagnostic panels can burden federal insurance programs, distort clinical records, expose beneficiaries to confusing results, and redirect limited resources away from medically supported services.
At the same time, aggressive criminal enforcement must distinguish intentional deception from reasonable medical judgment or operational error, especially when regulations evolved rapidly, and healthcare businesses were asked to scale nationwide services under unprecedented public pressure.
That balance makes a public jury trial important, because prosecutors must present admissible evidence openly, defense counsel can cross-examine witnesses, and jurors can evaluate competing explanations under instructions designed to protect the presumption of innocence.
Reputation, Compliance, and Public Accountability
The convergence of a healthcare indictment, a civil default judgment, an aviation conviction, and a pending new-trial motion has created a lasting online record showing why executives facing investigations need disciplined legal communication alongside rigorous evidence preservation and operational review.
Resources addressing crisis public-relations planning emphasize coordinated, accurate communication during rapidly developing disputes, while guidance on reputation rebuilding underscores that credible recovery depends upon lawful conduct, verified facts, stakeholder transparency, and sustained accountability rather than cosmetic suppression.
For laboratories and healthcare entrepreneurs, the practical lesson is that marketing promises, physician orders, medical-necessity determinations, test-performance records, claims submissions, and transfers between related companies must remain consistent enough to survive review by auditors, insurers, investigators, judges, and jurors.
Compliance programs should therefore identify who authorizes testing, who validates claims, how deceased-patient files are blocked, how exceptions are documented, and how executives receive warnings before questionable patterns become financially significant or legally indefensible.
Independent auditing becomes especially important when reimbursement rises abruptly, because extraordinary revenue may reflect successful service expansion, yet it can also signal coding errors, unsupported add-on testing, duplicated work, or incentives that have drifted away from patient care.
What Happens on October 13
When jury selection begins, prospective jurors will likely face questions about pandemic experiences, Medicare, nursing homes, laboratory testing, AeroVanti publicity, and Britton-Harr’s prior conviction, with the court seeking participants capable of deciding only the healthcare charges presented.
Opening statements should reveal whether prosecutors organize the case around patient examples, physician denials, claims analytics, financial transfers, or corporate communications, while the defense will outline which links in that chain it believes the government cannot prove beyond a reasonable doubt.
The five healthcare fraud counts and single money-laundering count expose Britton-Harr to substantial additional punishment if convicted, although a federal judge would later determine any sentence by considering statutory factors, advisory guidelines, proven loss, and his overall record.
An acquittal would not erase the civil judgment or AeroVanti verdict, just as those earlier outcomes cannot lawfully decide the healthcare indictment, because each proceeding carries distinct claims, evidence, burdens, defenses, and appellate pathways.
Until the October trial concludes, the central proposition remains an allegation: prosecutors say a nationwide nursing-home testing offer enabled millions of dollars in false Medicare billing, while Britton-Harr retains the right to confront that evidence before an impartial jury.
The proceeding will test whether the government can transform a complicated record of pandemic laboratory operations into proof of deliberate healthcare fraud and money laundering, making October 13 a pivotal date in a legal saga already spanning medicine, aviation, corporate finance, and federal enforcement.
